IMCR Stock: Price, Earnings History and SEC Filings
Immunocore Holdings plc (IMCR) last traded at $30.49, down 2.49% on the latest session and up 0.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.02 against an analyst estimate of $-0.01, a miss of 100.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IMCR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.02 | $-0.01 | -100.00% |
| Mar 2026 | May 6, 2026 | $0.25 | $-0.26 | +196.15% |
| Dec 2025 | Feb 25, 2026 | $-0.60 | $-0.28 | -114.29% |
| Sep 2025 | Nov 6, 2025 | $0.00 | $-0.30 | +100.00% |
IMCR beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How IMCR reacts to earnings
Across its last 8 earnings releases, IMCR moved 3.7% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | +3.63% |
| 2026-05-06 | Before open | +6.55% |
| 2026-02-25 | Before open | -4.51% |
| 2026-01-09 | Before open | -0.15% |
| 2025-11-06 | Before open | +2.58% |
| 2025-08-07 | Before open | -0.53% |
| 2025-05-07 | Before open | +6.63% |
| 2025-02-26 | Before open | +5.34% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
IMCR financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $400M | -$36M | -$15M | -8.9% | $-0.71 |
| 2024 | $310M | -$51M | $21M | -16.5% | $-1.02 |
| 2023 | $249M | -$55M | -$2M | -22.2% | $-1.13 |
| 2022 | $174M | -$53M | -$51M | -30.1% | $-1.15 |
| 2021 | $4M | -$180M | -$144M | -4414.6% | $-4.24 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for IMCR
- 8-K · Sep 14, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · May 27, 2026Shareholder vote
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 6, 2026
- DEF 14A · Apr 16, 2026
- 8-K · Feb 25, 2026Results of operations, Financial statements and exhibits
- 10-K · Feb 25, 2026
- 8-K · Jan 30, 2026Officer or director change
Insider filing activity
IMCR insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
IMCR news
- Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meetingOct 29, 2026 · finance.yahoo.com
- Should First Type 1 Diabetes Dosing Require Action From Immunocore Stock Investors?Oct 29, 2026 · finance.yahoo.com
About Immunocore Holdings plc
Immunocore Holdings plc (IMCR) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in United Kingdom. Its fiscal year ends in December.